Reversing mutations in a protein linked to cancer risk
Refolding Mutant p53: A Strategy for Cancer Prevention in Li-Fraumeni Syndrome
['FUNDING_OTHER'] · RESEARCH INST OF FOX CHASE CAN CTR · NIH-11174990
This study is exploring a new way to help people with certain genetic mutations that affect the VHL protein, which can increase cancer risk, by developing compounds that might help the protein work better and reduce the chances of cancer.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | RESEARCH INST OF FOX CHASE CAN CTR (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-11174990 on ClinicalTrials.gov |
What this research studies
This research investigates a new approach to counteract the effects of genetic mutations in the von Hippel-Lindau (VHL) protein, which is associated with an increased risk of various cancers. By utilizing advanced computational modeling and structure-based methods, the team aims to develop compounds that can stabilize the active form of the VHL protein, potentially restoring its function. This could lead to significant advancements in cancer prevention strategies for individuals with hereditary mutations. The research focuses on patients with specific mutations that affect the VHL protein's ability to suppress tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with germline mutations in the VHL gene or those at high risk for cancers linked to these mutations.
Not a fit: Patients without VHL mutations or those with cancers unrelated to VHL may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel therapeutic strategy for preventing cancers associated with VHL mutations.
How similar studies have performed: Previous research has shown promise in using computational methods to develop therapies targeting similar genetic mutations, indicating potential for success in this novel approach.
Where this research is happening
PHILADELPHIA, UNITED STATES
- RESEARCH INST OF FOX CHASE CAN CTR — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CLAPPER, MARGIE L. — RESEARCH INST OF FOX CHASE CAN CTR
- Study coordinator: CLAPPER, MARGIE L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers